A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
for Advanced Solid Tumor
5 locations incl. Scottsdale
Sponsor: GI Innovation, Inc.
Sex: All·Age: 18+
Code: NCT05824975·Phase 1, Phase 2·Recruiting